Evidence map›Paper›PMID 40302186›Full record

ArticleIET systems biology

SAE1 May Play a Pro-Carcinogenic Role in Pancreatic Adenocarcinoma: A Comprehensive Study Integrating Multiple Pieces of Evidence.

Yi Chen, Tong Wu, Qi Li, Ming-Jie Li, Na Yu, Li-Jueyi Meng, Xian-Jin Chen, Bang-Teng Chi, Shi-De Li, Su-Ning Huang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IET systems biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. BMJ open gastroenterology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yi ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Tong WuDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Qi LiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ming-Jie LiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Na YuDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Li-Jueyi MengDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xian-Jin ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Bang-Teng ChiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shi-De LiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Su-Ning HuangDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.
Gang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yu-Ping YeKey Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Dan-Ming WeiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.ORCID 0000-0002-2180-9226

Funding

China Undergraduate Innovation and Entrepreneurship Training Program S202410598212Future Academic Star of Guangxi Medical University WLXSZX24118Guangxi Educational Science Planning Key Project 2022ZJY2791Guangxi Higher Education Undergraduate Teaching Reform Project 2022JGA146Guangxi Medical University Undergraduate Education and Teaching Reform Project 2023Z10Guangxi Zhuang Autonomous Region Administration of Traditional Chinese Medicine Scientific Research Project GXZYA20230267Guangxi Zhuang Autonomous Region Administration of Traditional Chinese Medicine Scientific Research Project GXZYA20230270Natural Science Foundation of Guangxi Province 2025GXNSFAA069660
6 · The paper itself

Abstract

SAE1, a key factor in tumour development, has not been thoroughly examined in pancreatic adenocarcinoma (PAAD), a cancer with high incidence and poor prognosis. We conducted a comprehensive study, integrating mRNA data, immunohistochemistry, CRISPR-modified cell line analysis and single-cell RNA sequencing to assess SAE1's role in PAAD. We also used ChIP-Seq to explore SAE1's transcriptional regulation and analysed clinical data, drug sensitivity and molecular docking models. SAE1 mRNA was significantly overexpressed in PAAD, with a substantial impact on cell proliferation and migration. Functional analyses linked SAE1 to cell cycle and DNA replication pathways, suggesting a role in PAAD development. Our study indicates that SAE1 may promote PAAD through cell cycle pathways, with FOXA1 potentially regulating SAE1's abnormal behaviour.

Indexed as

AdenocarcinomaCarcinogenesisPancreatic NeoplasmsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-alphaHumansMolecular Docking SimulationFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphacell cyclepancreatic adenocarcinomaRNA‐SeqscRNA‐SeqSUMO1 activating enzyme subunit 1

Identifiers

PMID40302186
PMCPMC12041129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.